


[Figure 3] Yearly changes in the percentage of second-line prescriptions (treatment changes from BG during 2012–2021)

Response rate(%); “Add SGLT2 inhibitors” added since 2015.

“Switch to BG/ DPP-4 inhibitors combination medications” and “Switch to other combination medications” added since 2015.



[Figure 3] Yearly changes in the percentage of second-line prescriptions (treatment changes from BG during 2012–2021)

Response rate(%); “Add SGLT2 inhibitors” added since 2015.

“Switch to BG/ DPP-4 inhibitors combination medications” and “Switch to other combination medications” added since 2015.

	2012 (n=172)	2013 (n=131)	2014 (n=155)	2015 (n=160)	2016 (n=207)	2017 (n=216)	2018 (n=227)	2019 (n=176)	2020 (n=270)	2021 (n=190)
Add SU	24.9	18.9	17.7	14.3	10.2	8.3	6.7	5.2	4.2	3.9
Add DPP-4 inhibitors	34.1	47	52.8	55.8	56	56.4	52.2	48.8	49.3	44.1
Add Thiazolidines	5.2	4.1	3.3	3.7	4	2.6	2.3	1.6	1.9	1.4
Add α -GI	9.1	7.3	7.9	6.9	6.3	5.4	4.6	3.3	2.8	2.5
Add Glinides	6	4	4.8	5	4.6	5	4.2	3.4	3.5	2.7
Switch to DPP-4 inhibitors(other than combination medications)	5.4	5.4	4.8	3.8	3.5	2.9	7.7	1.8	1.6	1.3
Switch to non-DPP-4 inhibitors(other than combination medications)	9.2	6.9	2.3	2.1	1.8	1.6	0.4	1	0.8	0.8
Switch to BG/DPP-4 inhibitors combination medications	-	-	-	-	-	-	1.9	10.5	11.1	13.4
Switch to other combination medications	-	-	-	-	-	-	1	0.9	1	0.7
Other	6.1	6.4	6.4	6.7	7.8	8.5	2.6	2.3	2.2	2.2
Add SGLT2 inhibitors	-	-	-	1.8	5.9	9.3	16.3	21.3	21.4	27